New-Generation Immunotherapy Anti-OX40 and Combination Treatments in Cancer Treatment

Our body contains and balances many complex processes to keep us healthy. The immune system is one of the foremost of these complex processes. Immune cells have developed a series of molecular checkpoints. Why are these checkpoints needed? They can activate the immune system by increasing defense against foreign invaders or prevent it from becoming strong enough to attack healthy cells.
Maintaining Balance in the Immune System
When the immune system encounters a virus or bacterium, it generally expels it from the body. Cancer, however, is different. Because cancer cells closely resemble healthy cells, the immune system cannot mount an adequate reaction. Consequently, cancer cells multiply and spread uncontrollably throughout the body.
Cancer immunotherapy changes the balance, activating the immune system to attack cancer cells while minimizing effects against healthy cells. However, the immune system is complex, and there are different pathways that influence this adjustment in both directions.
T Cell Support
The aim of immunotherapy is to harness the power of immune cells that recognize and attack cancer cells, namely T cells. To do this, T cells first need to be activated. Antigen-presenting cells are specialized immune cells that display cancer-specific proteins (antigens), enabling T cells to recognize the target to attack. This also triggers a series of cellular events activating T cells.
The research discussed here targets this process. When T cells are presented with antigens, the protein on the cell surface called OX40 helps increase T cell activity. Activation of the immune system can be increased with the immunotherapy drug called Anti-OX40 (despite its name, an antibody that binds OX40 and activates it). Unlike the recently discovered antibodies beginning to be used in treating various cancers, anti-CTLA4 (ipilimumab), anti-PD1 (nivolumab, pembrolizumab) and anti-PDL1 (atezolizumab), anti-OX40acts by activating the molecule (OX40) to which it binds.
Strengthening immune system activation

One effect of Anti-OX40 is thought to be increasing the number of T cells that can be activated to find and attack cancer cells.
Anti-OX40 may extend the lifespan of T cells. This means the cells can live longer and have more time to develop cellular memory against cancer antigens. With cellular memory, a faster and stronger immune response against cancer cells can be produced when they are encountered again.
An additional benefit of Anti-OX40 may be increasing production of immune system alarm signals called cytokines. Anti-OX40 may help T cells produce certain cytokines, such as interferon gamma, known to have antitumor properties.
Reducing Barriers Facing the Immune System
Tools increasing immune system activation, such as Anti-OX40, hold promise in cancer treatment. However, sometimes focusing on actions is not enough to change the outcome.
One difficulty encountered with immunotherapy is that cancer is clever and develops various ways to hide from the immune system. An example is the protein called PD-L1, used by cancer cells to overcome the immune barrier. It does this by binding to and inactivating proteins called PD-1 and B7.1 on T cell surfaces.
Another type of immunotherapy uses antibodies preventing the PD-L1 protein from binding to PD-1 and B7.1 proteins on T cells (called anti-PDL1). Anti-PDL1 drugs can enable T cells to recognize and attack cancer cells, thus mobilizing the immune system to fight cancer. One of these drugs, Atezolizumab, received FDA approval on 18 May 2016 for treating stage 4 bladder cancer.

Combined immunotherapies
Today, cancer immunotherapy is approached from different angles by targeting more than one step in the immune system cycle, and combined approaches that may best help the immune system attack certain cancer types are evaluated. These immunotherapy approaches can also affect healthy cells. Scientists therefore continue their research on the subject.

It is thought that increasing activation with Anti-OX40 and reducing inhibition with anti-PDL1 may reveal a way to change immune system actions and make significant progress in cancer treatment.
Sources
Rationale for anti-OX40 cancer immunotherapy.
Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.